Therapeutic and Diagnostic Proteases Engineering Services

Proteases play a pivotal role in modern medicine, serving as powerful tools for Peptide Drug Processing, Enzyme Replacement Therapy (ERT), and high-precision diagnostics. Unlike traditional small molecules, therapeutic proteases offer unparalleled catalytic efficiency for clearing pathogenic proteins or activating prodrugs. However, their clinical utility is frequently challenged by rapid in vivo degradation, suboptimal substrate specificity leading to off-target toxicity, and potential immunogenicity that triggers adverse patient responses.

Our specialized enzyme engineering and optimization services are designed to transform natural proteases into robust clinical candidates. We focus on enhancing serum stability, refining cleavage specificity for target-only modification, and performing surface engineering to mask immunogenic epitopes. Partner with us to accelerate your protease-based drug development through advanced molecular evolution and rational design.

Get a Quote

Clinical Challenges Engineering Focus Technology Platforms Project Flow FAQ

Challenges in Therapeutic Protease Development

The transition of proteases from the laboratory to the clinic is often hindered by critical pharmacological and immunological barriers:

In Vivo Susceptibility: Therapeutic proteases are often recognized as substrates by endogenous serum proteases, leading to a short half-life and the need for frequent dosing.
Off-Target Proteolysis: Low substrate specificity can result in the unintended cleavage of essential physiological proteins, causing systemic toxicity.
Immunogenicity: Proteases derived from non-human sources or even engineered human variants can be recognized by the immune system, inducing neutralizing antibodies.
Complex Delivery Requirements: Ensuring the protease remains active within specific cellular compartments or physiological pH ranges requires sophisticated enzyme formulation stabilization services.

Our platform addresses these bottlenecks by integrating computational modeling with high-throughput experimental validation.

Engineering Focus: Optimized Proteolytic Performance

We apply targeted engineering strategies to create next-generation proteases with enhanced therapeutic indexes:

Enhanced In Vivo Stability

We utilize enzyme stability engineering to introduce disulfide bonds or hydrophobic packing that protects the protease from autolysis and serum degradation.

Substrate Specificity Tuning

Through enzyme active site engineering, we reshape the S1-S4 pockets to recognize only the specific peptide sequences found in target biomarkers or pathogenic proteins.

De-immunization

By employing surface engineering and in silico epitope mapping, we identify and replace high-risk immunogenic residues to reduce the risk of anti-drug antibody (ADA) formation.

Kinetic Profile Optimization

We fine-tune the turnover rate (kcat) and affinity (Km) to ensure the protease operates efficiently under physiological substrate concentrations.

Technology Platforms for Protease Engineering

Our suite of technologies allows for the precise directed evolution and rational design of therapeutic enzymes:

Computational Rational Design (CARD)

We leverage CARD technology to predict mutations that enhance the protease-substrate binding energy while avoiding off-target interactions.

Continuous Evolution (PACE)

Our PACE technology enables the rapid evolution of protease variants through hundreds of generations, ideal for selecting for high catalytic efficiency.

Droplet Microfluidic Screening

We utilize FADS technology to screen protease libraries with ultra-high throughput, isolating variants with superior selectivity in simulated serum environments.

AI-Driven Function Prediction

Using AI-driven discovery services, we identify novel protease scaffolds with intrinsic resistance to degradation from vast genomic databases.

Comprehensive Profiling

Our protease profiling services characterize the engineered variants against broad peptide libraries to ensure zero cross-reactivity with host proteins.

Project Flow: Protease Optimization Workflow

We manage therapeutic protease development through a milestone-driven, transparent process:

Target Alignment: Defining the target cleavage sequence, desired half-life in serum, and acceptable immunogenicity thresholds.
Design & Simulation: Performing in silico modeling of the protease-target interaction and mapping potential immunogenic epitopes.
Library Synthesis: Constructing focused mutagenesis libraries targeting the active site and surface-exposed residues.
High-Throughput Selection: Employing specialized selection pressures (e.g., serum incubation) to identify variants with enhanced fitness.
Lead Characterization: Rigorous validation of leads using enzyme kinetic profiling and stability assays in human plasma.

Every project is supported by comprehensive documentation suitable for regulatory filings and downstream development. We provide:

Detailed reports on substrate specificity (P4-P4' mapping) and off-target analysis.
Stability data across various temperatures, pH levels, and serum concentrations.
Mutagenesis strategy summaries and detailed sequencing data for all lead variants.

FAQ: Protease Engineering

Common questions regarding therapeutic protease optimization.

How do you specifically increase a protease's resistance to serum degradation?

We use a combination of surface charge modification and the introduction of non-canonical amino acids or site-specific modifications to prevent recognition by endogenous degradative enzymes.

Can you engineer proteases to be "switchable" or conditionally active?

Yes. By incorporating allosteric regulation or pH-sensitive domains, we can design proteases that remain inactive in the blood but activate upon reaching the acidic environment of a tumor or lysosome.

What methods do you use to reduce the immunogenicity of a protease?

We utilize B-cell and T-cell epitope prediction algorithms to identify "hotspots" on the protein surface and replace them with less immunogenic residues without compromising catalytic activity.

How do you ensure that a therapeutic protease doesn't cleave host proteins?

We perform rigorous substrate profiling against the human proteome and use negative selection during directed evolution to eliminate variants with broad or promiscuous activity.

Is it possible to engineer proteases for diagnostic biosensors?

Absolutely. We can optimize proteases for high sensitivity and rapid turnover, making them ideal for detection systems where a specific biomarker cleavage triggers a signal.

Which protease families are your platforms compatible with?

Our platforms are versatile and compatible with serine, cysteine, aspartic, and metalloproteases, including specialized classes like granzymes and caspases.

What is the typical timeline for a de-immunization and stability project?

A comprehensive optimization project usually takes 20-35 weeks, covering everything from in silico design to validation in human serum models.

Do you offer recombinant expression and purification for these engineered proteases?

Yes, we provide specialized expression services to ensure high yields of correctly folded, active proteases, including those requiring zymogen activation.